Search clinical trials for: CMV specific T-cells

Total 1852 results

Hrain Biotechnology Co., Ltd.
Shanghai Changzheng Hospital

Active, not recruiting

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES

POMES Syndrome | Relapsed and Refractory POMES Syndrome

China
GlaxoSmithKline

Completed

A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma (NY-ESO-1)

Neoplasms

United States
The Second Affiliated Hospital of Henan University...
First Affiliated Hospital of Wenzhou Medical University; Second Affiliated... and other collaborators

Unknown

Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL

CD19-positive ALL

China
Memorial Sloan Kettering Cancer Center
Otsuka America Pharmaceutical; Ludwig Institute for Cancer Research

Completed

Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions

Multiple Myeloma

United States
Mansoura University

Completed

The Association Between Obstructive Sleep Apnea Severity and Red Blood Cells Indices

Obstructive Sleep Apnea

Egypt
Stanford University
Kyverna Therapeutics

Recruiting

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

Multiple Sclerosis | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary Progressive

United States
Turnstone Biologics, Corp.

Recruiting

A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors (STARLING)

Breast Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Uveal Melanoma | Cutaneous Melanoma

United States, Canada
The Affiliated People's Hospital of Ningbo University
UTC Therapeutics Inc.

Recruiting

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

Lymphoma | Leukemia | Myeloma | Relapsed/Refractory Hematological Malignancies

China
Shanghai 6th People's Hospital
Hrain Biotechnology Co., Ltd.

Recruiting

The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer

Ovarian Cancer

China
Shanghai Pudong Hospital
UTC Therapeutics Inc.

Withdrawn

Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

Mesothelin-positive Advanced Refractory Solid Tumors

China
Masonic Cancer Center, University of Minnesota

Completed

Trial of Indole-3-Carbinol and Silibinin

Smoking

United States
Chinese PLA General Hospital

Unknown

Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden

Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden

China
Peng Liu
Shanghai East Hospital; Hrain Biotechnology

Unknown

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM

Multiple Myeloma in Relapse | Multiple Myeloma Progression

China
Shenzhen Second People's Hospital
Shenzhen Institute for Innovation and Translational Medicine

Unknown

Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia

China
Jonsson Comprehensive Cancer Center
Parker Institute for Cancer Immunotherapy; City of Hope National Medical Center and other collaborators

Recruiting

Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Metastatic Melanoma | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8

United States
Wuhan Union Hospital, China
Guangzhou Bio-gene Technology Co., Ltd

Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy

Multiple Myeloma

China
Sabz Biomedicals
Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical... and other collaborators

Not yet recruiting

CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Relapsed B Cell Acute Lymphoblastic Leukemia (ALL) | Refractory B Cell Acute Lymphoblastic Leukemia (ALL)

Iran, Islamic Republic of
Xinqiao Hospital of Chongqing
The First Affiliated Hospital of Anhui Medical University; Nanfang Hospital... and other collaborators

Recruiting

Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies

T-cell Lymphoma | T-cell Leukemia

China
Hrain Biotechnology Co., Ltd.
Shanghai Changzheng Hospital

Recruiting

BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

China
Imugene Limited

Recruiting

Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL

Non-Hodgkin Lymphoma | B-cell Acute Lymphoblastic Leukemia

United States
Fujian Cancer Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Unknown

EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC

Nasopharyngeal Carcinoma

China
Beijing Sanbo Brain Hospital
Marino Biotechnology Co., Ltd.

Unknown

Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme

Glioblastoma Multiforme

China
CARsgen Therapeutics Co., Ltd.
Fudan University; Peking University Cancer Hospital & Institute

Recruiting

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

Pancreatic Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
Inge Marie Svane

Unknown

TIL Therapy for Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

Denmark
National Cancer Institute (NCI)

Completed

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes

Melanoma | Skin Cancer

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI); Susan G. Komen Breast Cancer Foundation

Terminated

Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer

Breast Cancer

United States
Providence Health & Services

Terminated

Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication

Multiple Sclerosis

United States
Second Military Medical University

Unknown

Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma | Recurrence Hepatocellular Carcinoma

China
National Research Center for Cardiac Surgery, Kazakhstan
Nazarbayev University Medical Center

Recruiting

Clinical, Functional, Immunological and Genetic Factors on the Severity of the Course of Coronavirus Infection

Covid19 | Corona Virus Infection

Kazakhstan
University of Bordeaux
Lundbeck France

Completed

Use of Selincro and Impact on Usual Practice (USE-PACT)

Alcohol Dependence

France
Indonesia University

Completed

Dihydroartemisinin-piperaquine and Primaquine for Uncomplicated Plasmodium Falciparum Cases (DHP+PQ)

Malaria

Indonesia
Marcela V. Maus, M.D.,Ph.D.

Recruiting

TriPRIL CAR T Cells in Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Multiple Myeloma in Relapse

United States
Xinqiao Hospital of Chongqing
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Not yet recruiting

Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

China
National Cancer Institute (NCI)

Recruiting

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Lymphoma, Non-Hodgkin | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Lymphoid Leukemia | B-Cell Leukemia | Leukemia, Lymphocytic, B Cell | B-Cell Lymphoma | B-All | B-NHL | B-Non Hodgkin Lymphoma

United States
Loyola University
Leukemia Research Foundation

Active, not recruiting

CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies

B-Cell Acute Lymphoblastic Leukemia, Adult | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

United States
Roger Williams Medical Center

Terminated

Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer

Lung Cancer

United States
Mayo Clinic

Recruiting

Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Beijing YouAn Hospital

Unknown

Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC

Hepatocellular Carcinoma

China
University of Nebraska

Terminated

Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation

Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Recruiting

Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies

Lymphoma, B-Cell | Chronic Lymphocytic Leukemia | B-Cell Chronic Lymphocytic Leukemia

United States
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia

Acute Lymphocytic Leukemia

China
UNC Lineberger Comprehensive Cancer Center

Recruiting

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Peripheral T Cell Lymphoma

United States
Shenzhen Second People's Hospital
Shenzhen Institute for Innovation and Translational Medicine

Unknown

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Melanoma | Breast Cancer | Multiple Myeloma | Ovarian Cancer | Lung Cancer | Neuroblastoma | Bladder Carcinoma | Synovial Sarcoma | Esophagus Carcinoma | Other Metastatic Solid Cancers

China
Taro Pharmaceuticals USA

Completed

Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study

Psoriasis

United States
Zhejiang Provincial People's Hospital

Recruiting

Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis

Rheumatoid Arthritis | Treatment Compliance | Abatacept

China
Shanxi Province Cancer Hospital
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma

Lymphoma, B-Cell

China
Bellicum Pharmaceuticals

Terminated

Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS (THRIVE)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Xinqiao Hospital of Chongqing
The First Affiliated Hospital of Anhui Medical University; Nanfang Hospital... and other collaborators

Unknown

Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies

B-cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
Karolinska University Hospital

Recruiting

T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma

Melanoma

Sweden
Dr. Soetomo General Hospital
Indonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, Indonesia

Recruiting

UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study)

COVID-19 Pandemic | COVID-19 Vaccines

Indonesia

Search clinical trials for: CMV specific T-cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations